Skip to main content
. Author manuscript; available in PMC: 2020 Aug 8.
Published in final edited form as: Cell. 2019 Aug 8;178(4):933–948.e14. doi: 10.1016/j.cell.2019.07.019

Figure 3. Preventing tumor IFN signaling promotes CD8 T cell-dependent and/or NK/ILC1-dependent ICB response.

Figure 3.

A) Survival of mice bearing CT26 tumors with KO of IFNGR +/− B2M or of both IFNGR and IFNAR (IFNA/GR) after no treatment (Cont), CD8 depletion (aCD8), or anti-PD1 (aPD1). For each group, n=5–15. B) Survival (top) and tumor volumes (bottom) after treatment with RT + anti-CTLA4 or control (Cont) for mice bearing B16 or Res 499 tumors with the indicated KO. Unless indicated, displayed p-values are for comparisons within each genotype (legend). For tumor volumes, only groups of interest are shown. Groups with no depletion: WT, n=20–28; IFNA/GR KO, n=10–20; IFNA/GR + B2M KO, n=4–5. For aNK1.1 groups, n=5. C) Tumor volumes for B16 and Res 499 tumors expressing human CD19 (hCD19) with or without IFNA/GR KO after a single infusion with primary murine T cells transduced with a CAR (CART) against hCD19. D) Survival of mice bearing IFNGR KO Res 499 tumors with or without concurrent B2M KO after treatment with anti-CTLA4. Effect of immune cell depletion with anti-CD8 or anti-NK1.1 is shown. IFNGR KO, n=5; B2M KO, n=5; IFNGR + B2M KO, n=10–20. E) Survival of wild type (WT) or Perforin KO (Prf1 KO) mice bearing IFNGR KO Res 499 tumors after anti-CTLA4. aCTLA4, n=7–10; Cont, n=2–4. See also Figure S3.